GLP-1 Drugs May Reach Only Half of Eligible Patients
Eli Lilly's CEO says structural barriers will cap GLP-1 weight-loss drug adoption at 40-50% of eligible patients, mirroring statin penetration rates.
1 article tagged "Weight Loss Drugs"
Eli Lilly's CEO says structural barriers will cap GLP-1 weight-loss drug adoption at 40-50% of eligible patients, mirroring statin penetration rates.